• Cornelia Bachmann, Bernhard Krämer, Sara Y Brucker, Anette Stäbler, Falko Fend, Diethelm Wallwiener, Eva Maria Grischke, and Ralf Rothmund.
• Department of Gynecology, University Tübingen, Tübingen, Germany cornelia.bachmann@med.uni-tuebingen.de.
• Anticancer Res. 2014 Nov 1; 34 (11): 6735-8.

AimTo delineate the relevance of pelvic and para-aortic node involvement in early-stage ovarian cancer.Patients And MethodsData on 75 consecutive patients with primary stage T1 and 2 ovarian cancer treated at the Department of Gynecology, University Tuebingen, Germany were retrospectively analyzed. All patients underwent stage-related surgery with pelvic and para-aortic lymphadenectomy and adjuvant platinum-based chemotherapy (except pT1aG1). Median follow up was 53.5 months. Clinico-pathological parameters and the distribution pattern of node metastases were evaluated. Statistical analyses were performed using PASW.ResultsLymph node metastases were detectable in T1 and T2 in 6 (8%) of 75 patients. Three patients (4%) had lymph node metastases in the pelvic nodes only, 2 patients (2.7%) in the para-aortic nodes only; 1 patient (1.3%) both in the pelvic and para-aortic nodes. On multivariate analysis, histological grade 1/ 2 and 3 tumors, serous and endometrioid histology were independent predictors for node metastases, respectively. The risk of relapse was significantly higher with detection of node metastases (p=0.004).ConclusionA systematic lymphadenectomy in early-stage ovarian cancer leads to an upstaging in a few patients after detection of node metastases even in pelvic or para-aortic nodes, especially in patients with grade 3 tumours and serous cancers. Pelvic and para-aortic lymphadenectomy may detect node involvement in early-stage ovarian cancer and might be helpful in correct staging.Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

42 keywords...

hide…